A federal appeals court yesterday upheld a patent board decision invalidating portions of a Johnson & Johnson (NYSE:JNJ) patent covering drug-eluting stents in a case that dates back to 2009. Wyeth, now part of Pfizer (NYSE:PFE), and onetime J&J subsidiary Cordis (which became a part of Cardinal Health in October 2015), sued Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX), alleging […]
Wyeth
Wyeth, Cordis bury the hatchet in stent patent spat with Abbott, Boston Scientific
A quartet of medical companies agreed yesterday to bury the hatchet in their 6-year-old battle over the patent covering drug-eluting stent technology. Wyeth, now part of Pfizer (NYSE:PFE), and onetime Johnson & Johnson (NYSE:JNJ) subsidiary Cordis (which this week became a part of Cardinal Health), sued Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) in 2009, alleging that […]
Federal Circuit denies re-hearing for Cordis patent claims against Medtronic, Abbott, Boston Scientific
A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.
Boston Scientific legal update: Guidant, Guidezilla and ongoing arguments
Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.
Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.
A trio of medical device giants notched another win against Johnson & Johnson(NYSE:JNJ) after a Federal Circuit judge upheld a lower court’s ruling that invalidated stent patents held by J&J subsidiary Cordis Corp.
Federal judge rules for Medtronic, Abbott, Boston Scientific over J&J in DES lawsuit | Legal News
A trio of med-tech titans logged a win against Johnson & Johnson (NYSE:JNJ) in a long-running battle over drug-eluting coronary stent patents.
Federal judge rules for Medtronic, Abbott, Boston Scientific over J&J in DES lawsuit
A trio of med-tech titans logged a win against Johnson & Johnson (NYSE:JNJ) in a long-running battle over drug-eluting coronary stent patents.
Appeals court backs BSX over Cordis | Legal Roundup
Appeals court backs Boston Scientific in patent spat with J&J’s Cordis Corp.
Stent Wars: Jersey judge denies Abbott/Boston Scientific move to stay stent suit
Federal judge: Four J&J patents invalid in infringement dispute with Boston Scientific
Boston Scientific Corp. (NYSE:BSX) won the latest round in its long-running patent war with Johnson & Johnson (NYSE:JNJ) when a federal judge declared invalid a quartet of J&J subsidiary Cordis Corp’s. patents for drug-eluting stents.
The patents in question are at the heart of complicated legal wrangling involving the Natick, Mass.-based medical device giant, its new Brunswick, N.J.-based rival, Abbott (NYSE:ABT) and Wyeth. The dispute centers around Boston Scientific’s Promus stent, a private-label version of Abbott’s Xience V stent, and the Cordis Cypher.
